Resources &


Paradigm conducts research and development days, investor roadshows, investor days, virtual conferences and webinars and clinical updates. To stay up to date with everything happening at Paradigm, join our mailing list.  

Next R&D Event

Last updated 22/09/2023 12:30pm

Next Investor Event

Last updated 26/10/2023 12:30pm

Upcoming Events

Shifts in Thinking

Read how the Paradigm team is approaching innovation from completely different approach below. For all published articles please click here

WorldSymposium Poster
Safety and tolerability of PPS in MPS VI
Author: Roberto Giugliani et al.
February 22, 2022
ICIEM Poster
Safety and tolerability of PPS in MPS I
Author: Drago Bratkovic et al.
November 22, 2021
Performance Report
J.P Morgan Healthcare Conference 2022
Author: Simon White
January 22, 2022
Development Plan
Potential of injectable PPS for knee OA
Author: Mukesh Ahuja MBBS, MS
May 22, 2022

Peer-Reviewed Publications

OARSI 2024 Podium Presentation
Source: Ahuja M et al.
April 20, 2024
OARSI 2024 Sponsored Theatre Symposium
Source: Ahuja M
April 19, 2024
PAINWeek 2023 Abstract
Source: Krishnan R, Skerrett D, Ahuja M, Duiker M, Sheehan M, Imperiale M
September 5, 2023
OARSI 2023 Sponsored Theatre Symposium
Source: Krishnan R & Ahuja M
March 18, 2023
Exploratory phase 2 trial suggests therapeutic effects for iPPS in knee osteoarthritis
Source: Ahuja M, et al
March 18, 2023
Results of an open-label phase 2 study evaluating PPS safety and tolerability in MPS I
Source: Bratkovic D, et al
March 14, 2023
OARSI 2023 Clinical Trial Symposium
Source: Skerrett D.
March 16, 2023
Phase 2 study evaluating PPS efficacy and safety in MPS VI
Source: Giugliani R, et al
February 24, 2023
MPS VI: defining and measuring functional impacts in pediatric patients
Source: Leiro B, et al
December 2, 2021
Double-blind placebo-controlled phase 2 study to evaluate the safety & tolerability of PPS in subjects with MPS VI
Source: Giugliani, R. et. al.
February 10, 2022
An open-label single-centre pilot study to evaluate the safety and tolerability of PPS in subjects with MPS I
Source: Bratkovic, D. et al
November 23, 2021
Summary of peer reviewed publications supporting PPS mechanism of action for the treatment of osteoarthritis
Source: Paradigm Biopharma
August 5, 2021

In the Media

Small Caps
Paradigm raises the stakes in osteoarthritis pain reduction
Focus: Osteoarthritis
August 15, 2018
WFAA USA reports on Paradigms’ Expanded Access
Focus: Expanded access
August 20, 2020
Footballers Chris Judd, Leo Barry pile into Paradigm Raising
Focus: Capital Raise
December 13, 2019
Report on Andrew Walker and Paradigms’ EAP in the USA
Focus: Osteoarthritis
August 26, 2020

Media Archive